A recent decision by the Fifth Circuit Court of Appeals has directed the FDA to restrict access to mifepristone. This decision may impact local residents who rely on this medication. Further details about the decision and its implications are available from the Guttmacher Institute, a local source of information on this topic. The institute has released a news statement regarding the Fifth Circuit Court of Appeals' directive to the FDA. For more information on the decision and its potential effects, readers can consult the Guttmacher Institute's news release, which provides additional context and details about the ruling.
choice
Fifth Circuit Decision Directs FDA to Restrict Mifepristone Access
A recent decision by the Fifth Circuit Court of Appeals has directed the FDA to restrict access to mifepristone. This decision may impact local residents who rely on this medication. Further details a